Metastatic treated malignant germ cell tumors: Is SALL4 a better marker than placental alkaline phosphatase?

Nicole Andeen, Maria S. Tretiakova

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Studies have shown that in the metastatic setting and after treatment, expression of immunohistochemical markers may be diminished or lost. Transcription factor SALL4 (sal-like protein 4) has been recognized as a sensitive marker for both primary and metastatic malignant germ cell tumors (MGCTs), but has not been tested in the posttreatment setting. We sought to determine the level of SALL4 expression in treatment-resistant metastatic MGCT in comparison with pan-GCT marker placental alkaline phosphatase (PLAP). Thirty-six previously treated MGCTs, 16 untreated primary testicular MGCTs, and 4 cytology specimens were immunostained for SALL4 and PLAP, and staining characteristics were evaluated. In the treated MGCT group, there was diffuse SALL4 nuclear immunoreactivity in the majority of cases (27/36, 75%), labeling seminoma, yolk-sac tumor, embryonal carcinoma, and primitive neuroectodermal components. No treated metastatic MGCT lacked SALL4 immunoreactivity. In contrast, PLAP was diffusely expressed in only 14/36 (39%) cases of treated MGCTs, showed scattered focal weak to moderate positivity in 13/36 (36%), and was virtually absent in 9/36 (25%) cases. Both markers had scattered expression limited to the epithelial components of teratomatous regions. SALL4 also outperformed PLAP on a small sample of cytology blocks. Although SALL4 is not entirely specific, it is a highly sensitive marker with strong diffuse nuclear reactivity in the majority of MGCTs in the posttreatment setting, at significantly higher levels than PLAP (P<0.001). Persistent expression of SALL4 in metastatic MGCTs resistant to chemoradiation also raises the possibility for targeted systemic therapy as the anti-SALL4 peptide continues to be developed.

Original languageEnglish (US)
Pages (from-to)210-214
Number of pages5
JournalApplied Immunohistochemistry and Molecular Morphology
Volume24
Issue number3
DOIs
StatePublished - Mar 23 2016
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Proteins
Cell Biology
Embryonal Carcinoma
Endodermal Sinus Tumor
Seminoma
placental alkaline phosphatase
Nuclear Proteins
Transcription Factors
Therapeutics
Staining and Labeling
Peptides

Keywords

  • diagnostic marker
  • germ cell tumor
  • PLAP
  • posttreatment
  • SALL4

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Medical Laboratory Technology

Cite this

Metastatic treated malignant germ cell tumors : Is SALL4 a better marker than placental alkaline phosphatase? / Andeen, Nicole; Tretiakova, Maria S.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 24, No. 3, 23.03.2016, p. 210-214.

Research output: Contribution to journalArticle

@article{4e611cc9932b4145aef8c6bb85fbb628,
title = "Metastatic treated malignant germ cell tumors: Is SALL4 a better marker than placental alkaline phosphatase?",
abstract = "Studies have shown that in the metastatic setting and after treatment, expression of immunohistochemical markers may be diminished or lost. Transcription factor SALL4 (sal-like protein 4) has been recognized as a sensitive marker for both primary and metastatic malignant germ cell tumors (MGCTs), but has not been tested in the posttreatment setting. We sought to determine the level of SALL4 expression in treatment-resistant metastatic MGCT in comparison with pan-GCT marker placental alkaline phosphatase (PLAP). Thirty-six previously treated MGCTs, 16 untreated primary testicular MGCTs, and 4 cytology specimens were immunostained for SALL4 and PLAP, and staining characteristics were evaluated. In the treated MGCT group, there was diffuse SALL4 nuclear immunoreactivity in the majority of cases (27/36, 75{\%}), labeling seminoma, yolk-sac tumor, embryonal carcinoma, and primitive neuroectodermal components. No treated metastatic MGCT lacked SALL4 immunoreactivity. In contrast, PLAP was diffusely expressed in only 14/36 (39{\%}) cases of treated MGCTs, showed scattered focal weak to moderate positivity in 13/36 (36{\%}), and was virtually absent in 9/36 (25{\%}) cases. Both markers had scattered expression limited to the epithelial components of teratomatous regions. SALL4 also outperformed PLAP on a small sample of cytology blocks. Although SALL4 is not entirely specific, it is a highly sensitive marker with strong diffuse nuclear reactivity in the majority of MGCTs in the posttreatment setting, at significantly higher levels than PLAP (P<0.001). Persistent expression of SALL4 in metastatic MGCTs resistant to chemoradiation also raises the possibility for targeted systemic therapy as the anti-SALL4 peptide continues to be developed.",
keywords = "diagnostic marker, germ cell tumor, PLAP, posttreatment, SALL4",
author = "Nicole Andeen and Tretiakova, {Maria S.}",
year = "2016",
month = "3",
day = "23",
doi = "10.1097/PAI.0000000000000174",
language = "English (US)",
volume = "24",
pages = "210--214",
journal = "Applied Immunohistochemistry",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Metastatic treated malignant germ cell tumors

T2 - Is SALL4 a better marker than placental alkaline phosphatase?

AU - Andeen, Nicole

AU - Tretiakova, Maria S.

PY - 2016/3/23

Y1 - 2016/3/23

N2 - Studies have shown that in the metastatic setting and after treatment, expression of immunohistochemical markers may be diminished or lost. Transcription factor SALL4 (sal-like protein 4) has been recognized as a sensitive marker for both primary and metastatic malignant germ cell tumors (MGCTs), but has not been tested in the posttreatment setting. We sought to determine the level of SALL4 expression in treatment-resistant metastatic MGCT in comparison with pan-GCT marker placental alkaline phosphatase (PLAP). Thirty-six previously treated MGCTs, 16 untreated primary testicular MGCTs, and 4 cytology specimens were immunostained for SALL4 and PLAP, and staining characteristics were evaluated. In the treated MGCT group, there was diffuse SALL4 nuclear immunoreactivity in the majority of cases (27/36, 75%), labeling seminoma, yolk-sac tumor, embryonal carcinoma, and primitive neuroectodermal components. No treated metastatic MGCT lacked SALL4 immunoreactivity. In contrast, PLAP was diffusely expressed in only 14/36 (39%) cases of treated MGCTs, showed scattered focal weak to moderate positivity in 13/36 (36%), and was virtually absent in 9/36 (25%) cases. Both markers had scattered expression limited to the epithelial components of teratomatous regions. SALL4 also outperformed PLAP on a small sample of cytology blocks. Although SALL4 is not entirely specific, it is a highly sensitive marker with strong diffuse nuclear reactivity in the majority of MGCTs in the posttreatment setting, at significantly higher levels than PLAP (P<0.001). Persistent expression of SALL4 in metastatic MGCTs resistant to chemoradiation also raises the possibility for targeted systemic therapy as the anti-SALL4 peptide continues to be developed.

AB - Studies have shown that in the metastatic setting and after treatment, expression of immunohistochemical markers may be diminished or lost. Transcription factor SALL4 (sal-like protein 4) has been recognized as a sensitive marker for both primary and metastatic malignant germ cell tumors (MGCTs), but has not been tested in the posttreatment setting. We sought to determine the level of SALL4 expression in treatment-resistant metastatic MGCT in comparison with pan-GCT marker placental alkaline phosphatase (PLAP). Thirty-six previously treated MGCTs, 16 untreated primary testicular MGCTs, and 4 cytology specimens were immunostained for SALL4 and PLAP, and staining characteristics were evaluated. In the treated MGCT group, there was diffuse SALL4 nuclear immunoreactivity in the majority of cases (27/36, 75%), labeling seminoma, yolk-sac tumor, embryonal carcinoma, and primitive neuroectodermal components. No treated metastatic MGCT lacked SALL4 immunoreactivity. In contrast, PLAP was diffusely expressed in only 14/36 (39%) cases of treated MGCTs, showed scattered focal weak to moderate positivity in 13/36 (36%), and was virtually absent in 9/36 (25%) cases. Both markers had scattered expression limited to the epithelial components of teratomatous regions. SALL4 also outperformed PLAP on a small sample of cytology blocks. Although SALL4 is not entirely specific, it is a highly sensitive marker with strong diffuse nuclear reactivity in the majority of MGCTs in the posttreatment setting, at significantly higher levels than PLAP (P<0.001). Persistent expression of SALL4 in metastatic MGCTs resistant to chemoradiation also raises the possibility for targeted systemic therapy as the anti-SALL4 peptide continues to be developed.

KW - diagnostic marker

KW - germ cell tumor

KW - PLAP

KW - posttreatment

KW - SALL4

UR - http://www.scopus.com/inward/record.url?scp=84962494994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962494994&partnerID=8YFLogxK

U2 - 10.1097/PAI.0000000000000174

DO - 10.1097/PAI.0000000000000174

M3 - Article

C2 - 25906119

AN - SCOPUS:84962494994

VL - 24

SP - 210

EP - 214

JO - Applied Immunohistochemistry

JF - Applied Immunohistochemistry

SN - 1541-2016

IS - 3

ER -